July. 27, 2020 |
|
Feb. 25, 2021 |
|
jRCTs051200036 |
Efficacy and safety of nintedanib on lung fibrosis in severe pneumonia induced by coronavirus disease 2019: Historical control study. |
|
Efficacy of nintedanib on severe COVID-19 pneumonia. |
Umemura Yutaka |
||
Osaka Genaral Medical Center |
||
3-1-56, Bandaihigashi, Sumiyoshiku, Osaka, Osaka |
||
+81-6-6692-1201 |
||
plum0022@yahoo.co.jp |
||
Umemura Yutaka |
||
Osaka |
||
3-1-56, Bandaihigashi, Sumiyoshiku, Osaka, Osaka |
||
+81-6-6692-1201 |
||
plum0022@yahoo.co.jp |
July. 29, 2020 |
||
30 | ||
Interventional |
||
single arm study |
||
open(masking not used) |
||
historical control |
||
single assignment |
||
treatment purpose |
||
none |
||
1) Obtaining sufficient informed consent for this trials from participates or their close relatives |
||
1) History of Idiopathic pulmonary fibrosis |
||
20age 0month 0week old over | ||
No limit | ||
Both |
||
Severe pneumonia induced by COVID-19 |
||
nintedanib |
||
nintedanib |
||
Administration of nintedanib via nasogastric tube |
||
COVID-19 |
||
COVID-19 |
||
28 days mortality after the initiation of mechanical ventilation |
||
1) Gastrointestinal adverse events within 28 days after adiministration of nintedanib |
Recruiting |
Osaka General Medical Center, Funding for research projects | |
Not applicable |
Medical Center Clinical Research Review Board | |
3-1-56, Bandaihigashi, Sumiyoshiku, Osaka, Osaka, Osaka | |
+81-6-6692-1201 |
|
kenkyu-crb@gh.opho.jp | |
Approval | |
July. 08, 2020 |
No |
|